FY2025 EPS Forecast for Ovid Therapeutics Cut by Analyst

Ovid Therapeutics (NASDAQ:OVID) – B. Riley lowered their FY2025 earnings per share (EPS) estimates for Ovid Therapeutics in a research report issued on Wednesday, November 12th. B. Riley analyst M. El-Saadi now expects that the company will earn ($0.46) per share for the year, down from their previous forecast of ($0.45). B. Riley currently has a “Buy” rating on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. B. Riley also issued estimates for Ovid Therapeutics’ FY2026 earnings at ($0.65) EPS.

A number of other research analysts also recently weighed in on OVID. Wall Street Zen downgraded Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Oppenheimer started coverage on Ovid Therapeutics in a research report on Thursday, October 9th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ovid Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $3.70.

Ovid Therapeutics Trading Up 8.8%

Ovid Therapeutics stock opened at $1.31 on Monday. Ovid Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24. The firm has a market capitalization of $92.93 million, a price-to-earnings ratio of -2.61 and a beta of 0.31. The company has a 50 day moving average price of $1.44 and a 200 day moving average price of $0.84.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Ovid Therapeutics had a negative return on equity of 63.79% and a negative net margin of 550.04%.The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.17 million.

Institutional Trading of Ovid Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC purchased a new stake in Ovid Therapeutics during the third quarter valued at about $1,148,000. Affinity Asset Advisors LLC purchased a new position in shares of Ovid Therapeutics in the first quarter worth approximately $208,000. Rosalind Advisors Inc. acquired a new stake in shares of Ovid Therapeutics during the second quarter valued at approximately $165,000. Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics by 112.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 924,576 shares of the company’s stock valued at $1,202,000 after acquiring an additional 488,956 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Ovid Therapeutics in the 3rd quarter valued at approximately $443,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.